To the Editor: Use of bisphosphonates for fracture prevention is increasing. These agents have potential adverse effects,1 but are not known to cause myocardial injury. We present a case of myopericarditis following administration of intravenous zoledronic acid.
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.